SCHEMBL2218229

SCHEMBL2218229

COCCn1c(-c2cccc(Cl)c2)c2c(=O)n(Cc3ccccc3)[nH]c2cc1=O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NOX4 Q9NPH5 10/20 0.49
ALDH1A1 P00352 5/20 0.43
CYP1A2 P05177 5/20 0.43
CYP3A4 P08684 5/20 0.43
HSD17B10 Q99714 4/20 0.43
CASP1 P29466 4/20 0.43
CYP2C9 P11712 4/20 0.43
CYP2C19 P33261 4/20 0.43
USP2 O75604 2/20 0.43
ALOX15 P16050 1/20 0.43
PGR P06401 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
CXCR2 P25025 1/20 0.40
CASP7 P55210 2/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16612317 0.82 NOX4 (0.58) NOX4CYP3A4CYP2C9CYP2C19
SCHEMBL2217664 0.79 NOX4 (0.51) NOX4ALDH1A1CYP1A2CYP3A4HSD17B10
SCHEMBL2220132 0.77 NOX4 (0.46) NOX4CYP2C9CYP2C19
SCHEMBL2218729 0.77 NOX4 (0.42) NOX4ALDH1A1CYP1A2CYP3A4HSD17B10
SCHEMBL2217987 0.77 NOX4 (0.49) NOX4CYP2C9CYP2C19
SCHEMBL2213401 0.76 NOX4 (0.51) NOX4ALDH1A1CYP1A2CYP3A4HSD17B10
SCHEMBL2218357 0.76 NOX4 (0.42) NOX4ALDH1A1CYP1A2CYP3A4HSD17B10
SCHEMBL2211989 0.76 NOX4 (0.47) NOX4ALDH1A1CYP1A2CYP3A4HSD17B10
SCHEMBL19956827 0.75 PGR (0.48) NOX4ALDH1A1CYP1A2CYP3A4HSD17B10
SCHEMBL2211909 0.75 NOX4 (0.49) NOX4ALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342203-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-11-04 EP claimed
US-8455486-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2013-06-04 US claimed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 US claimed
EP-2342203-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-11-04 EP disclosed
EP-2342203-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-11-04 EP disclosed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 US disclosed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 US disclosed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 US disclosed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 US disclosed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 US disclosed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 US disclosed
US-8455486-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2013-06-04 US disclosed
US-8455486-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2013-06-04 US disclosed
US-8455486-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2013-06-04 US disclosed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 US disclosed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 US disclosed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 US disclosed
WO-2010035220-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB NOX4 2/4885ALDH1A1 230/4885CYP1A2 63/4885
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB NOX4 2/4885ALDH1A1 230/4885CYP1A2 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.